Search results for "GIS"

showing 10 items of 7190 documents

Young Adult and Usual Adult Body Mass Index and Multiple Myeloma Risk: A Pooled Analysis in the International Multiple Myeloma Consortium (IMMC)

2017

AbstractBackground: Multiple myeloma risk increases with higher adult body mass index (BMI). Emerging evidence also supports an association of young adult BMI with multiple myeloma. We undertook a pooled analysis of eight case–control studies to further evaluate anthropometric multiple myeloma risk factors, including young adult BMI.Methods: We conducted multivariable logistic regression analysis of usual adult anthropometric measures of 2,318 multiple myeloma cases and 9,609 controls, and of young adult BMI (age 25 or 30 years) for 1,164 cases and 3,629 controls.Results: In the pooled sample, multiple myeloma risk was positively associated with usual adult BMI; risk increased 9% per 5-kg/m…

0301 basic medicineMaleobesityprocedureEpidemiologygroups by ageOverweightcancer riskBody Mass Index[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicinestudy designRisk Factorsmiddle agedYoung adultrisk factor AdultMultiple myeloma2. Zero hungereducation.field_of_studyanthropometryadultrisk assessment3. Good healthmultiple myelomafemaleOncologypriority journal030220 oncology & carcinogenesisyoung adultmedicine.symptomCase-Control Studiemedicine.medical_specialtymultivariate logistic regression analysiPopulation[SDV.CAN]Life Sciences [q-bio]/CancerArticle03 medical and health sciencesInternal medicinemedicineHumanshumaneducationAgedbusiness.industryCase-control studyAnthropometrycase control studymedicine.diseaseConfidence interval030104 developmental biologyEndocrinologyCase-Control StudiespathologybusinessBody mass indexbody ma
researchProduct

In vitro activity of anidulafungin in combination with amphotericin B or voriconazole against biofilms of five Candida species

2016

Objectives: To evaluate the in vitro activity of anidulafungin combined with amphotericin B or voriconazole against Candida spp. biofilms. Methods: Four Candida albicans, four Candida tropicalis, four Candida glabrata, two Candida parapsilosis and two Candida orthopsilosis blood isolates were tested by the microdilution chequerboard method combined with the XTT metabolic assay. Biofilm MIC was defined as the lowest concentration producing 50% metabolic inhibition with respect to control (BMIC50). Concentrations in the combinations ranged from 1/8xBMIC(50) to 4xBMIC(50) found for each antifungal tested alone. Results: Anidulafungin plus amphotericin B acted synergistically against C. albican…

0301 basic medicineMicrobiology (medical)Antifungal Agents030106 microbiologyMicrobial Sensitivity TestsCandida parapsilosisAnidulafunginMicrobiologyCandida tropicalis03 medical and health sciencesEchinocandinsAmphotericin BAmphotericin BmedicineHumansPharmacology (medical)Candida albicansCandidaPharmacologyVoriconazolebiologyCandida glabrataChemistryCandidemiaDrug Synergismbiology.organism_classificationbacterial infections and mycosesCorpus albicansInfectious DiseasesBiofilmsAnidulafunginVoriconazolemedicine.drug
researchProduct

Gut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivo

2018

Source at https://doi.org/10.3389/fmicb.2018.00530 . Background: Statin has been widely used to treat hyperlipidemia because of its high potency in decreasing cholesterol levels. The present study aimed to examine the lipid-lowering effect of rosuvastatin and the composition, diversity and species abundance of gut microbiome in association with rosuvastatin efficacy. TRIAL REGISTRATION: ChiCTR-ORC-17013212 at the First Affiliated Hospital of Dalian Medical University, November 2, 2017. Results:Totally 64 patients with hyperlipidemia were treated with 10 mg/day of rosuvastatin for 4-8 weeks. Blood lipid indicators triglycerides (TG), total cholesterol (TC), high density lipoprotein (HDL), lo…

0301 basic medicineMicrobiology (medical)Statinmedicine.drug_classlcsh:QR1-502PhysiologyBlood lipidsgut microbiomeBiologyGut floraMicrobiologylcsh:Microbiology03 medical and health scienceschemistry.chemical_compoundHigh-density lipoproteinHyperlipidemiamedicinehyperlipidemiaRosuvastatinVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Cardiology: 771VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Kardiologi: 771CholesterolVDP::Medical disciplines: 700::Basic medical dental and veterinary science disciplines: 710::Pharmacology: 728nutritional and metabolic diseasesFusobacteriaVDP::Medical disciplines: 700::Basic medical dental and veterinary science disciplines: 710::Medical microbiology: 715medicine.diseasebiology.organism_classification16S rRNA sequencing030104 developmental biologychemistryVDP::Medisinske Fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710::Medisinsk mikrobiologi: 715VDP::Medisinske Fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710::Farmakologi: 728lipids (amino acids peptides and proteins)hypolipidemic effectrosuvastatinmedicine.drugFrontiers in Microbiology
researchProduct

Clinical and Imaging Features of Adults with Recurrent Pulmonary Tuberculosis - A Prospective Case-Controlled Study

2021

Background: Recurrent pulmonary tuberculosis (RPTB) is a growing, important and neglected problem affecting treated TB patients and TB health services across the world, particularly in sub-Saharan Africa. Analyses and identification of differences in clinical features between recurrent PTB and newly diagnosed PTB may lead to improved management recommendations. Methods: Between September 1st 2019 and January 31st 2020, we performed a prospective case controlled study of clinical and imaging features of patients with recurrent pulmonary tuberculosis and compared them with those of newly diagnosed PTB cases. Recurrent PTB was defined as a patient with bacteriologically confirmed active PTB wh…

0301 basic medicineMicrobiology (medical)medicine.medical_specialty030106 microbiologyInfectious and parasitic diseasesRC109-216Lung injuryChest painLogistic regressionImagingClinical03 medical and health sciences0302 clinical medicinePulmonary tuberculosisInternal medicineHumansMedicine030212 general & internal medicineTuberculosis PulmonaryLung functionLungbusiness.industryAssociated factorsPulmonary tuberculosisCase-control studyGeneral MedicineInfectious Diseasesmedicine.anatomical_structureRadiological weaponmedicine.symptomRecurrentbusinessInternational Journal of Infectious Diseases
researchProduct

The role of mitochondrial reactive oxygen species, NO and H2S in ischaemia/reperfusion injury and cardioprotection

2020

Redox signalling in mitochondria plays an important role in myocardial ischaemia/reperfusion (I/R) injury and in cardioprotection. Reactive oxygen and nitrogen species (ROS/RNS) modify cellular structures and functions by means of covalent changes in proteins including among others S‐nitros(yl)ation by nitric oxide (NO) and its derivatives, and S‐sulphydration by hydrogen sulphide (H2S). Many enzymes are involved in the mitochondrial formation and handling of ROS, NO and H2S under physiological and pathological conditions. In particular, the balance between formation and removal of reactive species is impaired during I/R favouring their accumulation. Therefore, various interventions aimed a…

0301 basic medicineMitochondrial ROSIschemiaEndogenyheartMitochondrionRedoxNitric oxide03 medical and health scienceschemistry.chemical_compound0302 clinical medicinenitric oxidemedicinechemistry.chemical_classificationCardioprotectionreactive oxygen speciesReactive oxygen speciesVDP::Medisinske Fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710Cell Biologymedicine.diseaseVDP::Medical disciplines: 700::Basic medical dental and veterinary science disciplines: 710Cell biologyreperfusionmitochondria030104 developmental biologychemistry030220 oncology & carcinogenesiscardioprotectionMolecular Medicineischaemiahydrogen sulphidecardioprotection; heart; hydrogen sulphide; ischaemia; mitochondria; nitric oxide; reactive oxygen species; reperfusion
researchProduct

Harmonising and linking biomedical and clinical data across disparate data archives to enable integrative cross-biobank research

2015

A wealth of biospecimen samples are stored in modern globally distributed biobanks. Biomedical researchers worldwide need to be able to combine the available resources to improve the power of large-scale studies. A prerequisite for this effort is to be able to search and access phenotypic, clinical and other information about samples that are currently stored at biobanks in an integrated manner. However, privacy issues together with heterogeneous information systems and the lack of agreed-upon vocabularies have made specimen searching across multiple biobanks extremely challenging. We describe three case studies where we have linked samples and sample descriptions in order to facilitate glo…

0301 basic medicineNetherlands Twin Register (NTR)Databases FactualComputer scienceInformation Storage and RetrievalSample (statistics)Ontology (information science)Endocrinology and DiabetesBioinformaticscomputer.software_genredata archivesArticle03 medical and health sciencesSDG 17 - Partnerships for the GoalsSDG 3 - Good Health and Well-beingGenetics/dk/atira/pure/keywords/cohort_studies/netherlands_twin_register_ntr_Use casebiomedical dataGenetics (clinical)Biological Specimen BanksGenetics & Heredity0604 GeneticsBioinformatics (Computational Biology)ta112ta1184/dk/atira/pure/sustainabledevelopmentgoals/partnershipsData scienceBiobank3. Good healthcross-biotank research030104 developmental biologyProject planningExchange of informationDisparate systemPrivacyBioinformatik (beräkningsbiologi)/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingclinical datacomputerData integrationEuropean Journal of Human Genetics
researchProduct

Factors influencing the development of visceral metastasis of breast cancer: A retrospective multi-center study.

2017

Abstract Purpose Visceral metastasis of breast cancer (BC) is an alarming development and correlates with poor median overall survival. The purpose of this retrospective study is to examine the risk factors for developing visceral metastasis by considering tumor biology and patient characteristics. Methods Using the BRENDA database, the risk factors such as histological and intrinsic subtypes of BC, age at primary diagnosis, grading, nodal status, tumor size and year of primary diagnosis were examined in univariate and multivariate analysis. Categorical variables were compared by using χ2 tests. Furthermore, multivariate Cox proportional hazards regression models, Kaplan–Meier product-limit…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPathologyMultivariate statisticsMultivariate analysisLung NeoplasmsBreast NeoplasmsKaplan-Meier EstimateLogistic regressionMetastasis03 medical and health sciencesYoung Adult0302 clinical medicineBreast cancerRisk FactorsInternal medicineMedicineHumansGrading (tumors)AgedProportional Hazards ModelsRetrospective StudiesAged 80 and overChi-Square Distributionbusiness.industryCarcinoma Ductal BreastLiver NeoplasmsUnivariateAge FactorsRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.disease030104 developmental biologyLogistic Models030220 oncology & carcinogenesisMultivariate AnalysisSurgeryFemalebusinessBreast (Edinburgh, Scotland)
researchProduct

Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French P…

2016

We aim to determine whether differences in survival exist between two populations of women with metastatic breast cancer (MBC) and to identify prognostic factors of survival after metastasis diagnosis. Data on women with MBC diagnosed between 2000 and 2011 were provided by the Cote d'Or Breast cancer registry. Survival rates and median overall survival (OS) after metastasis diagnosis were determined using the Kaplan–Meier method and prognostic factors were determined in a Cox proportional hazard model. Overall, 282 women with primary MBC and 340 with secondary MBC were included. A 2-year survival rate was significantly better in women with primary MBC (50.8% [95% CI: 47.8–53.8%] versus 44.5…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPopulationBreast NeoplasmsDiseaseKaplan-Meier EstimateMetastasis03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineEpidemiologyInternal MedicinemedicineHumansRegistriesskin and connective tissue diseaseseducationSurvival rateAgedProportional Hazards ModelsAged 80 and overeducation.field_of_studyProportional hazards modelbusiness.industryNeoplasms Second PrimaryMiddle Agedmedicine.diseasePrognosisMetastatic breast cancerSurvival Rate030104 developmental biologyOncology030220 oncology & carcinogenesisSurgeryFemaleFrancebusinessThe breast journal
researchProduct

Type and gene location of kit mutations predict progression-free survival to first-line imatinib in gastrointestinal stromal tumors: A look into the …

2021

In previous studies on localized GISTs, KIT exon 11 deletions and mutations involving codons 557/558 showed an adverse prognostic influence on recurrence-free survival. In the metastatic setting, there are limited data on how mutation type and codon location might contribute to progression-free survival (PFS) variability to first-line imatinib treatment. We analyzed the type and gene location of KIT and PDGFRA mutations for 206 patients from a GIST System database prospectively collected at an Italian reference center between January 2005 and September 2020. By describing the mutational landscape, we focused on clinicopathological characteristics according to the critical mutations and inve…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyStromal cellPDGFRAlcsh:RC254-28203 medical and health sciencesExon0302 clinical medicinePredictive biomarkersInternal medicineGene duplicationmedicineGastrointestinal stromal tumorsProgression-free survivalGeneneoplasmsGiSTbusiness.industryImatinibKITlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncology030220 oncology & carcinogenesisImatinibbusinessMutationsmedicine.drugGIST
researchProduct

Response: Methods for second primary cancers evaluation have to be standardized

2017

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industryIncidence (epidemiology)Endometrial cancerCancerSecond primary cancermedicine.diseaseSecond Primary CancersCancer registry03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineEpidemiology of cancermedicineEtiologybusinessInternational Journal of Cancer
researchProduct